Complete Genomics' human genome sequencing service has been used by Institute for Systems Biology (ISB) to sequence a family quartet to determine the depth of genetic information possible in analyzing a full family's sequence, and to verify the gene responsible for Miller syndrome, a rare craniofacial disorder.
Results from this collaboration will be published online later today in the journal Science; the manuscript is titled "Analysis of Genetic Inheritance in a Family Quartet by Whole Genome Sequencing.""We are convinced that this new kind of analysis, family sequencing, will be a remarkably powerful scientific and medical tool in the future. ISB was delighted to work closely with the group at Complete Genomics to generate the data that enabled us to complete this study," said David Galas, Professor and Senior Vice President of ISB.
AdvertisementISB used Complete Genomics' service to sequence the genomes of a four-member nuclear family in which the two children suffer from Miller syndrome and ciliary dyskinesia, a lung disorder similar to cystic fibrosis, but neither parent is affected. The goal of this study was to identify rare genetic variations that could be responsible for Miller syndrome, and to estimate the intergenerational mutation rate.
Complete Genomics sequenced the four genomes to a depth of 51x to 88x, and 85-92% of the bases in each genome were called. A comparative analysis of the four genomes yielded four genes consistent with recessive inheritance of rare variations. One of these genes, DHODH, was concurrently identified as a cause of Miller syndrome [Nat Genet. 2010 Jan;42(1):13-4]. Mutations in a second gene, DNAH5, have previously been shown to cause primary ciliary dyskinesia.
"When we established Complete Genomics, our goal was to provide large-scale complete human genome sequencing as a service that would enable our customers to make medically-relevant discoveries. We are delighted that ISB is already making breakthroughs of that caliber from its first study using our service," said Dr. Clifford Reid, chairman, president and CEO of Complete Genomics. "This is the type of positive disruptive influence that we want our technology to have on medical research."
You May Also Like